Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-03-30

AUTHORS

R. De Vecchis, C. Esposito, C. Ariano, S. Cantatrione

ABSTRACT

BackgroundIn advanced congestive heart failure (CHF), intravenous (i.v.) inotropic agents, i.v. diuretics, ultrafiltration, and hemodialysis have been shown to not yield better clinical outcomes. In this scenario, the simultaneous administration of hypertonic saline solution (HSS) and furosemide may offer a more effective therapeutic option with a good safety profile.MethodsTherefore, a meta-analysis was performed to compare combined therapy, consisting of i.v. furosemide plus concomitant administration of HSS, with i.v. furosemide alone for acute decompensated heart failure (ADHF). The outcomes we chose were all-cause mortality, risk of re-hospitalization for ADHF, length of hospital stay, weight loss, and variation of serum creatinine.ResultsBased on five randomized controlled trials (RCTs) involving 1,032 patients treated with i.v. HSS plus furosemide vs. 1,032 patients treated with i.v. furosemide alone, a decrease in all-cause mortality in patients treated with HSS plus furosemide was proven [RR = 0.57; 95 % confidence interval (CI) = 0.44–0.74, p = 0.0003]. Likewise, combined therapy with HSS plus furosemide was shown to be associated with a reduced risk of ADHF-related re-hospitalization (RR = 0.51; 95 % CI = 0.35–0.75, p = 0.001). Besides, combined therapy with HSS plus furosemide was found to be associated with a reduced length of hospital stay (p = 0.0002), greater weight loss (p < 0.00001), and better preservation of renal function (p < 0.00001).ConclusionHSS as an adjunct to i.v. furosemide for diuretic-resistant CHF patients led to a better renal safety profile and improved clinical endpoints such as mortality and heart failure-related hospitalizations. More... »

PAGES

423-435

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-013-4041-6

DOI

http://dx.doi.org/10.1007/s00059-013-4041-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017213941

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24682291


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comorbidity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diuretics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Furosemide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospital Mortality", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Length of Stay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renal Insufficiency", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Saline Solution, Hypertonic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Vecchis", 
        "givenName": "R.", 
        "id": "sg:person.0704361014.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Hygiene and Preventive Medicine, Second University of Naples, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/grid.9841.4", 
          "name": [
            "Institute of Hygiene and Preventive Medicine, Second University of Naples, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Esposito", 
        "givenName": "C.", 
        "id": "sg:person.01135016617.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135016617.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ariano", 
        "givenName": "C.", 
        "id": "sg:person.0660263343.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cantatrione", 
        "givenName": "S.", 
        "id": "sg:person.01113703526.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113703526.58"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00134-008-1206-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023251276", 
          "https://doi.org/10.1007/s00134-008-1206-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00059-010-3394-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009543748", 
          "https://doi.org/10.1007/s00059-010-3394-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199100413-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017857196", 
          "https://doi.org/10.2165/00003495-199100413-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11897-010-0018-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011836956", 
          "https://doi.org/10.1007/s11897-010-0018-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-200525030-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032161722", 
          "https://doi.org/10.2165/00044011-200525030-00002"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-03-30", 
    "datePublishedReg": "2014-03-30", 
    "description": "BackgroundIn advanced congestive heart failure (CHF), intravenous (i.v.) inotropic agents, i.v. diuretics, ultrafiltration, and hemodialysis have been shown to not yield better clinical outcomes. In this scenario, the simultaneous administration of hypertonic saline solution (HSS) and furosemide may offer a more effective therapeutic option with a good safety profile.MethodsTherefore, a meta-analysis was performed to compare combined therapy, consisting of i.v. furosemide plus concomitant administration of HSS, with i.v. furosemide alone for acute decompensated heart failure (ADHF). The outcomes we chose were all-cause mortality, risk of re-hospitalization for ADHF, length of hospital stay, weight loss, and variation of serum creatinine.ResultsBased on five randomized controlled trials (RCTs) involving 1,032 patients treated with i.v. HSS plus furosemide vs. 1,032 patients treated with i.v. furosemide alone, a decrease in all-cause mortality in patients treated with HSS plus furosemide was proven [RR =\u20090.57; 95\u2009% confidence interval (CI) =\u20090.44\u20130.74, p\u2009=\u20090.0003]. Likewise, combined therapy with HSS plus furosemide was shown to be associated with a reduced risk of ADHF-related re-hospitalization (RR =\u20090.51; 95\u2009% CI =\u20090.35\u20130.75, p\u2009=\u20090.001). Besides, combined therapy with HSS plus furosemide was found to be associated with a reduced length of hospital stay (p\u2009=\u20090.0002), greater weight loss (p\u2009<\u20090.00001), and better preservation of renal function (p\u2009<\u20090.00001).ConclusionHSS as an adjunct to i.v. furosemide for diuretic-resistant CHF patients led to a better renal safety profile and improved clinical endpoints such as mortality and heart failure-related hospitalizations.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-013-4041-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "40"
      }
    ], 
    "keywords": [
      "acute decompensated heart failure", 
      "hypertonic saline solution", 
      "decompensated heart failure", 
      "renal safety profile", 
      "congestive heart failure", 
      "heart failure", 
      "safety profile", 
      "cause mortality", 
      "hospital stay", 
      "clinical outcomes", 
      "good renal safety profile", 
      "heart failure-related hospitalizations", 
      "weight loss", 
      "intravenous inotropic agents", 
      "effective therapeutic option", 
      "better clinical outcomes", 
      "good safety profile", 
      "greater weight loss", 
      "serum creatinine", 
      "renal function", 
      "CHF patients", 
      "concomitant administration", 
      "inotropic agents", 
      "therapeutic options", 
      "combined therapy", 
      "clinical endpoints", 
      "hypertonic saline", 
      "simultaneous administration", 
      "patients", 
      "furosemide", 
      "therapy", 
      "mortality", 
      "stay", 
      "outcomes", 
      "saline solution", 
      "administration", 
      "risk", 
      "better preservation", 
      "failure", 
      "diuretics", 
      "hospitalization", 
      "hemodialysis", 
      "creatinine", 
      "adjunct", 
      "trials", 
      "endpoint", 
      "saline", 
      "BackgroundIn", 
      "profile", 
      "loss", 
      "options", 
      "agents", 
      "decrease", 
      "preservation", 
      "length", 
      "function", 
      "ultrafiltration", 
      "variation", 
      "scenarios", 
      "solution", 
      "risk of ADHF", 
      "ConclusionHSS", 
      "diuretic-resistant CHF patients", 
      "failure-related hospitalizations"
    ], 
    "name": "Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure", 
    "pagination": "423-435", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017213941"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-013-4041-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24682291"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-013-4041-6", 
      "https://app.dimensions.ai/details/publication/pub.1017213941"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_617.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-013-4041-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-013-4041-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-013-4041-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-013-4041-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-013-4041-6'


 

This table displays all metadata directly associated to this object as RDF triples.

238 TRIPLES      22 PREDICATES      112 URIs      98 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-013-4041-6 schema:about N0fc1e9d664064022885e4fab2ad4193a
2 N2f30b141418b4869a0b3e0912be1e62f
3 N365c3420b61444c18badc598c3ac6286
4 N4255b19ca61a41aaa78d9d30cb96492e
5 N468ed5a5e2bd414a90fff9ad67e912e5
6 N739177a3f134461297f5864c9635189b
7 N8651b75bbf1e42dd931cec26c7bb28a8
8 N91736ae74b5c49e0b5e8c850361ef16a
9 N976c194769664d7e9f47d6504dc949ee
10 N9d07dce237c0488b8f8a0974cd3e145f
11 Nb2e63a8c114c467987f4c4f798fac5df
12 Nb8c588b8fd9545ac9f692eecf7ec08a6
13 Nd62516fc39094645ae460ebb5c148b41
14 Nd694e95a45264e7facc5993fd7f6025d
15 Ne2a40b98281045f1952517180a70029a
16 Ne5ad199982f14d24926fa15cafe568b3
17 anzsrc-for:11
18 anzsrc-for:1102
19 anzsrc-for:1103
20 schema:author Nda8a361242b441ceb74bce62760d5aca
21 schema:citation sg:pub.10.1007/s00059-010-3394-3
22 sg:pub.10.1007/s00134-008-1206-5
23 sg:pub.10.1007/s11897-010-0018-4
24 sg:pub.10.2165/00003495-199100413-00003
25 sg:pub.10.2165/00044011-200525030-00002
26 schema:datePublished 2014-03-30
27 schema:datePublishedReg 2014-03-30
28 schema:description BackgroundIn advanced congestive heart failure (CHF), intravenous (i.v.) inotropic agents, i.v. diuretics, ultrafiltration, and hemodialysis have been shown to not yield better clinical outcomes. In this scenario, the simultaneous administration of hypertonic saline solution (HSS) and furosemide may offer a more effective therapeutic option with a good safety profile.MethodsTherefore, a meta-analysis was performed to compare combined therapy, consisting of i.v. furosemide plus concomitant administration of HSS, with i.v. furosemide alone for acute decompensated heart failure (ADHF). The outcomes we chose were all-cause mortality, risk of re-hospitalization for ADHF, length of hospital stay, weight loss, and variation of serum creatinine.ResultsBased on five randomized controlled trials (RCTs) involving 1,032 patients treated with i.v. HSS plus furosemide vs. 1,032 patients treated with i.v. furosemide alone, a decrease in all-cause mortality in patients treated with HSS plus furosemide was proven [RR = 0.57; 95 % confidence interval (CI) = 0.44–0.74, p = 0.0003]. Likewise, combined therapy with HSS plus furosemide was shown to be associated with a reduced risk of ADHF-related re-hospitalization (RR = 0.51; 95 % CI = 0.35–0.75, p = 0.001). Besides, combined therapy with HSS plus furosemide was found to be associated with a reduced length of hospital stay (p = 0.0002), greater weight loss (p < 0.00001), and better preservation of renal function (p < 0.00001).ConclusionHSS as an adjunct to i.v. furosemide for diuretic-resistant CHF patients led to a better renal safety profile and improved clinical endpoints such as mortality and heart failure-related hospitalizations.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N2df4b43b1f5042bfbe594aa6ba249285
33 N3394aa15a93e4afd89bb8192e26b1664
34 sg:journal.1087175
35 schema:keywords BackgroundIn
36 CHF patients
37 ConclusionHSS
38 acute decompensated heart failure
39 adjunct
40 administration
41 agents
42 better clinical outcomes
43 better preservation
44 cause mortality
45 clinical endpoints
46 clinical outcomes
47 combined therapy
48 concomitant administration
49 congestive heart failure
50 creatinine
51 decompensated heart failure
52 decrease
53 diuretic-resistant CHF patients
54 diuretics
55 effective therapeutic option
56 endpoint
57 failure
58 failure-related hospitalizations
59 function
60 furosemide
61 good renal safety profile
62 good safety profile
63 greater weight loss
64 heart failure
65 heart failure-related hospitalizations
66 hemodialysis
67 hospital stay
68 hospitalization
69 hypertonic saline
70 hypertonic saline solution
71 inotropic agents
72 intravenous inotropic agents
73 length
74 loss
75 mortality
76 options
77 outcomes
78 patients
79 preservation
80 profile
81 renal function
82 renal safety profile
83 risk
84 risk of ADHF
85 safety profile
86 saline
87 saline solution
88 scenarios
89 serum creatinine
90 simultaneous administration
91 solution
92 stay
93 therapeutic options
94 therapy
95 trials
96 ultrafiltration
97 variation
98 weight loss
99 schema:name Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure
100 schema:pagination 423-435
101 schema:productId N44f969c49aa04e2ba7062da7652c04b6
102 N535c61a9384a4f9280bcdb2864fc0640
103 N85c25196a4f84280b8a862657dc10add
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017213941
105 https://doi.org/10.1007/s00059-013-4041-6
106 schema:sdDatePublished 2022-01-01T18:33
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher Nd82310ac13d14fdb8f3569d4f9a23c4b
109 schema:url https://doi.org/10.1007/s00059-013-4041-6
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N0fc1e9d664064022885e4fab2ad4193a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Heart Failure
115 rdf:type schema:DefinedTerm
116 N2df4b43b1f5042bfbe594aa6ba249285 schema:issueNumber 3
117 rdf:type schema:PublicationIssue
118 N2f30b141418b4869a0b3e0912be1e62f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Male
120 rdf:type schema:DefinedTerm
121 N3394aa15a93e4afd89bb8192e26b1664 schema:volumeNumber 40
122 rdf:type schema:PublicationVolume
123 N365c3420b61444c18badc598c3ac6286 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Saline Solution, Hypertonic
125 rdf:type schema:DefinedTerm
126 N4255b19ca61a41aaa78d9d30cb96492e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Female
128 rdf:type schema:DefinedTerm
129 N44f969c49aa04e2ba7062da7652c04b6 schema:name pubmed_id
130 schema:value 24682291
131 rdf:type schema:PropertyValue
132 N468ed5a5e2bd414a90fff9ad67e912e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Renal Insufficiency
134 rdf:type schema:DefinedTerm
135 N535c61a9384a4f9280bcdb2864fc0640 schema:name doi
136 schema:value 10.1007/s00059-013-4041-6
137 rdf:type schema:PropertyValue
138 N739177a3f134461297f5864c9635189b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Survival Rate
140 rdf:type schema:DefinedTerm
141 N85c25196a4f84280b8a862657dc10add schema:name dimensions_id
142 schema:value pub.1017213941
143 rdf:type schema:PropertyValue
144 N8651b75bbf1e42dd931cec26c7bb28a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Comorbidity
146 rdf:type schema:DefinedTerm
147 N91736ae74b5c49e0b5e8c850361ef16a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 N976c194769664d7e9f47d6504dc949ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Randomized Controlled Trials as Topic
152 rdf:type schema:DefinedTerm
153 N9d07dce237c0488b8f8a0974cd3e145f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Incidence
155 rdf:type schema:DefinedTerm
156 Nb2e63a8c114c467987f4c4f798fac5df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Drug Therapy, Combination
158 rdf:type schema:DefinedTerm
159 Nb8c588b8fd9545ac9f692eecf7ec08a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Length of Stay
161 rdf:type schema:DefinedTerm
162 Nbe9a997e24584958bb66059e295bdf15 rdf:first sg:person.0660263343.51
163 rdf:rest Ndb8c7dad12714d3e839fc4b2051af6ec
164 Nc61dd9cd301f4d81bc6a6e7ff6908b70 rdf:first sg:person.01135016617.34
165 rdf:rest Nbe9a997e24584958bb66059e295bdf15
166 Nd62516fc39094645ae460ebb5c148b41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Hospital Mortality
168 rdf:type schema:DefinedTerm
169 Nd694e95a45264e7facc5993fd7f6025d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Treatment Outcome
171 rdf:type schema:DefinedTerm
172 Nd82310ac13d14fdb8f3569d4f9a23c4b schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 Nda8a361242b441ceb74bce62760d5aca rdf:first sg:person.0704361014.79
175 rdf:rest Nc61dd9cd301f4d81bc6a6e7ff6908b70
176 Ndb8c7dad12714d3e839fc4b2051af6ec rdf:first sg:person.01113703526.58
177 rdf:rest rdf:nil
178 Ne2a40b98281045f1952517180a70029a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Furosemide
180 rdf:type schema:DefinedTerm
181 Ne5ad199982f14d24926fa15cafe568b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Diuretics
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
188 schema:name Cardiorespiratory Medicine and Haematology
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
191 schema:name Clinical Sciences
192 rdf:type schema:DefinedTerm
193 sg:journal.1087175 schema:issn 0340-9937
194 1615-6692
195 schema:name Herz
196 schema:publisher Springer Nature
197 rdf:type schema:Periodical
198 sg:person.01113703526.58 schema:affiliation grid-institutes:None
199 schema:familyName Cantatrione
200 schema:givenName S.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113703526.58
202 rdf:type schema:Person
203 sg:person.01135016617.34 schema:affiliation grid-institutes:grid.9841.4
204 schema:familyName Esposito
205 schema:givenName C.
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135016617.34
207 rdf:type schema:Person
208 sg:person.0660263343.51 schema:affiliation grid-institutes:None
209 schema:familyName Ariano
210 schema:givenName C.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51
212 rdf:type schema:Person
213 sg:person.0704361014.79 schema:affiliation grid-institutes:None
214 schema:familyName De Vecchis
215 schema:givenName R.
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79
217 rdf:type schema:Person
218 sg:pub.10.1007/s00059-010-3394-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009543748
219 https://doi.org/10.1007/s00059-010-3394-3
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s00134-008-1206-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023251276
222 https://doi.org/10.1007/s00134-008-1206-5
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s11897-010-0018-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011836956
225 https://doi.org/10.1007/s11897-010-0018-4
226 rdf:type schema:CreativeWork
227 sg:pub.10.2165/00003495-199100413-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017857196
228 https://doi.org/10.2165/00003495-199100413-00003
229 rdf:type schema:CreativeWork
230 sg:pub.10.2165/00044011-200525030-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032161722
231 https://doi.org/10.2165/00044011-200525030-00002
232 rdf:type schema:CreativeWork
233 grid-institutes:None schema:alternateName Cardiology Unit, Presidio Sanitario Intermedio “Elena d’Aosta”, Naples, Italy
234 schema:name Cardiology Unit, Presidio Sanitario Intermedio “Elena d’Aosta”, Naples, Italy
235 rdf:type schema:Organization
236 grid-institutes:grid.9841.4 schema:alternateName Institute of Hygiene and Preventive Medicine, Second University of Naples, Naples, Italy
237 schema:name Institute of Hygiene and Preventive Medicine, Second University of Naples, Naples, Italy
238 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...